摘要
目的通过测定急性白血病(AL)患儿脱氧胞苷激酶(DCK)和胞苷脱氨酶(CDA)基因的表达,探讨其与阿糖胞苷(Ara-C)耐药及临床疗效间的关系。方法应用RT-PCR方法检测32例AL患儿DCK和CDA基因mRNA表达水平,采用ANO VA比较初治与复发及不同亚型白血病患儿间DCK和CDA基因表达的差异。结果ALL患儿DCK表达水平(1.914±0.127)明显高于AML患儿(0.838±0.093 P=0),初治患儿DCK基因表达水平(1.474±0.547)为复发患儿(0.778±0.059)的2倍。AL患儿CDA基因表达水平为0.518±0.107,初治与复发以及各亚型间无显著性差异(P>0.05)。初治患儿CDA/DCK比值(0.422±0.049)明显低于复发患者(0.640±0.031 P=0.001),经DA或HA方案治疗1、2疗程缓解的AML患儿CDA/DCK比值低于未缓解患儿(0.561±0.053vs0.728±0.066 P=0)。结论DCK基因表达水平、CDA/DCK比值可作为监测AL儿童对Ara-C治疗反应一个指标。
Objective To investigate the expression of deoxycytidine kinase（DCK） and cytidine deaminase （CDA） gene in children with acute leukemia and to explore the relationship between gene expression and clinical response to cytarabine（Ara-C）. Methods Semiquantity reverse transcription polymerase chain reaction （RT-PCR） was used to detect the expression level of DCK and CDA in 32 children （including 17 ALL, 15 AML,27 previously untreated and 5 relapsed patients）. Results The average expression of DCK in ALL children was significantly higher than that of children with AML （ 1.914±0.127 vs 0.838± 0.093 P=0 ）. It was about 2 times in previously untreated group than in relapsed group （1.474±0.547 vs 0.778±0.059 ）. The level of CDA was 0.518±0.107 in whole cohort. There was no significance between previously untreated group and relapsed group. So was in different morpholngic subtype groups （P〉0.05）. The ratio of CDA/DCK in previously untreated children was much lower than that of relapsed children （0.422±0.049 vs 0.640±0.031 P=0.001 ）. AML children in complete remission（OR） after treatment with one to two DA or HA regimen had lower CDA/DCK ratio than non-CR patients （0.561±0.053 vs 0.728±0.066 P=0）.Conclusion The level of DCK expression and the ratio of CDA/DCK may be the predictors of treatment response to Ara-C containing regimen in children with acute leukemia.
出处
《实用儿科临床杂志》
CAS
CSCD
北大核心
2006年第15期973-974,1001,共3页
Journal of Applied Clinical Pediatrics
基金
上海市科委项目资助(034119920)
